1st Mar 2019 10:05
LONDON (Alliance News) - Biotechnology company MaxCyte Inc on Friday said it has expanded its business relationship with Kite by signing a multi-drug clinical and commercial agreement.
Under the terms of the deal, Kite will use MaxCyte's flow electroporation technology to enable non-viral cell engineering in the development of multiple drug candidates for up to 10 targets.
Kite will obtain non-exclusive clinical and commercial-use rights in exchange for sales-based payments and other licensing fees.
"We're excited to take our relationship with Kite further into product development, providing the company the ability to leverage MaxCyte's versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics," MaxCyte's President & Chief Executive Doug Doerfler said.
The two companies have been cooperating since November 2018, when they entered an exclusive research agreement.
MaxCyte shares were untraded on Friday, last quoted at 176.00 pence each.
Related Shares:
MaxCyte